{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.83","upperLimit":"7.69","value":"7.16"},{"groupId":"OG001","lowerLimit":"6.93","upperLimit":"8.12","value":"7.13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"222"}],"units":"Participants"}],"description":"PFS was calculated for all randomized patients from the day of randomization until the first observation of disease progression (date of objective relapse or progression of Relapse/Progression Report) or death due to any cause (recorded in Date/Cause of Death Section of Death Report). The primary analysis for PFS was based on the progression evaluated in this study using mesothelioma-modified RECIST (mRECIST) conducted by blinded independent review (BICR).","dispersionType":"95% Confidence Interval","groups":[{"description":"Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles\n\nCisplatin\n\nPemetrexed","id":"OG000","title":"Arm A - Cisplatin/Pemetrexed"},{"description":"Pembrolizumab 200 mg\\* IV Day 1 over 30 min every 21 days for a total of 2 years Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles\n\nCisplatin\n\nPemetrexed\n\nPembrolizumab","id":"OG001","title":"Arm B - Cisplatin/Pemetrexed/Pembrolizumab"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"PFS was monitored continuously, with assessments every 6 weeks for 3 visits, then every 12 weeks, 4 weeks post-discontinuation, every 12 weeks until progression, and every 24 weeks until death, over an average of 16.2 months.","title":"Phase III: Progression Free Survival Measured as Time From Randomization to First Observation of Objective Disease Relapse or Progression","type":"SECONDARY","unitOfMeasure":"months"}